Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?

Emanuel Raschi¹, Paolo Caraceni^{2

3

4}

Affiliations

¹ Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
² Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
³ IRCCS AOU di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.
⁴ Center for Biomedical Applied Research, Alma Mater Studiorum - University of Bologna, Bologna, Italy.

Comment

Emanuel Raschi et al. Hepatology. 2022 Jul.

. 2022 Jul;76(1):E25-E26.

doi: 10.1002/hep.32407. Epub 2022 Feb 27.

Emanuel Raschi¹, Paolo Caraceni^{2

3

4}

¹ Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
² Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
³ IRCCS AOU di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.
⁴ Center for Biomedical Applied Research, Alma Mater Studiorum - University of Bologna, Bologna, Italy.

No abstract available

Comment on

Letter to the editor: A revised electronic version of RUCAM for the diagnosis of drug-induced liver injury.
Devarbhavi H, Kurien SS. Devarbhavi H, et al. Hepatology. 2022 Oct;76(4):E71-E72. doi: 10.1002/hep.32522. Epub 2022 Jun 10. Hepatology. 2022. PMID: 35451140 No abstract available.

1. Hayashi PH, Lucena MI, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, et al. A revised electronic version of RUCAM for the diagnosis of drug induced liver injury. Hepatology. 2022;76:18-31.
1. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590-603.
1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222-61.
1. Teschke R, Danan G. Idiosyncratic drug induced liver injury, cytochrome P450, metabolic risk factors and lipophilicity: highlights and controversies. Int J Mol Sci. 2021;22(7):3441.
1. Gatti M, Poluzzi E, De Ponti F, Raschi E. Liver injury with ulipristal acetate: exploring the underlying pharmacological basis. Drug Saf. 2020;43(12):1277-85.